Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancerenglish
- To determine the level of evidence supporting the clinical validity and utility for the profiling assays in question
- To determine whether certain breast cancer patient populations in Ontario would benefit from alternative tests (in addition to Oncotype DX)
Women diagnosed with invasive early-stage breast cancer for whom further information is needed for treatment decision making
Intended Guideline Users
Clinicians, policy makers, and the Ontario Ministry of Health and Long-Term Care
- Given that there are now multiple multigene assays that can predict for recurrence in patients with invasive breast cancer, what is the level of evidence supporting the clinical validity and utility for each of these assays?
- Given that Oncotype DX is part of standard practice in Ontario, what is the evidence that other assays can complement or replace Oncotype DX for certain clinical utilities?